Zacks David N, Ezra Eric, Terada Yoshiko, Michaud Norman, Connolly Edward, Gragoudas Evangelos S, Miller Joan W
Retina Service and Angiogenesis Laboratory, Massachusetts Eye and Ear Infirmary, Harvard Medical School, 243 Charles Street, Boston, MA 02114, USA.
Invest Ophthalmol Vis Sci. 2002 Jul;43(7):2384-91.
To develop a model of verteporfin photodynamic therapy (PDT) for experimental choroidal neovascularization CNV in the rat.
A laser injury model was used to induce experimental CNV in rats. The transit and accumulation of the photosensitizer verteporfin was assessed angiographically in CNV lesions, to determine the optimal time for delivery of light energy. The CNV lesions were then treated with verteporfin PDT, with two doses of verteporfin (3.0 and 6.0 mg/m(2)) and four activating doses of light energy (10, 25, 50, and 100 J/cm(2)). Closure of the CNV was assessed both angiographically and histologically. Verteporfin PDT was also performed on areas of normal choroid and retina at the two verteporfin doses and four light energy doses. The effect of these treatments on these structures was also assessed angiographically and histologically.
Peak verteporfin intensities in the CNV were detected at 15 to 20 minutes after intravenous injection. Rates of closure of the CNV varied as a function of the dose of verteporfin and of the activating light energy. Angiographic closure of the CNV correlated with damage to the neovascular complex, as seen with light and electron microscopy. Damage to areas of normal choroid and retina treated with verteporfin PDT also varied as a function of the verteporfin and light energy doses.
Verteporfin PDT for experimental CNV in the rat is a feasible, effective, and reproducible model that can be used for testing the efficacy of adjunctive therapy to verteporfin PDT.
建立大鼠实验性脉络膜新生血管（CNV）的维替泊芬光动力疗法（PDT）模型。
采用激光损伤模型诱导大鼠实验性CNV。通过血管造影评估光敏剂维替泊芬在CNV病变中的转运和蓄积情况，以确定输送光能的最佳时间。然后用维替泊芬PDT治疗CNV病变，使用两种剂量的维替泊芬（3.0和6.0mg/m²）和四种激活光能剂量（10、25、50和100J/cm²）。通过血管造影和组织学评估CNV的闭合情况。还在两种维替泊芬剂量和四种光能剂量下对正常脉络膜和视网膜区域进行维替泊芬PDT治疗。通过血管造影和组织学评估这些治疗对这些结构的影响。
静脉注射后15至20分钟在CNV中检测到维替泊芬的峰值强度。CNV的闭合率随维替泊芬剂量和激活光能的变化而变化。如光学显微镜和电子显微镜所见，CNV的血管造影闭合与新生血管复合体的损伤相关。用维替泊芬PDT治疗的正常脉络膜和视网膜区域的损伤也随维替泊芬和光能剂量的变化而变化。
大鼠实验性CNV的维替泊芬PDT是一种可行、有效且可重复的模型，可用于测试维替泊芬PDT辅助治疗的疗效。
